¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"orphan drug"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® antianginal drug ÇÑ±Û Ç×Çù½ÉÁõÁ¦
¼³¸í   
  Çù½ÉÁõÀº ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°ÔÇϰųª ½ÉÀåÀÌ Ç÷·ù¿¡ ºñÇØ¼­ ¸¹Àº ÀÏÀ» Çϴ °ÍÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Ä¡·áµÉ ¼ö ÀÖ´Ù. ¨ç nitrate°èÅëÀÇ ¾à¹°: Ç÷°üÀ» À̿ϽÃ۴ ÀÛ¿ëÀ» ÇÔÀ¸·Î½á ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù. ¨è Ä®½·Åë·ÎÂ÷´ÜÁ¦(verapamil, nifedipine): ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â CaÀÌ °ü¿©ÇÑ´Ù. Áï CaÀÌ ÀÖ¾î¾ß¸¸ ±ÙÀ°ÀÇ ¼öÃàÀÌ °¡´ÉÇØÁø´Ù. ±×·¯¹Ç·Î CaÀÌ ¼¼Æ÷¼ÓÀ¸·Î µé¾î°¡´Â °ÍÀ» ¾ïÁ¦Çϴ ¾àÁ¦´Â ±ÙÀ°ÀÇ ¼öÃàÀ» ¸·´Â´Ù. ÀÌ ¾àÀº ½ÉÀåÀÇ ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ½ÉÀå ±ÙÀ°ÀÇ ¼öÃàÀ» ¾ïÁ¦Çϸ砽ÉÀåÀÌ °úµµÇϰԠÀÏÇϴ °ÍÀ» ¸·°í, ¶Ç ½ÉÀ嵿¸ÆÀÇ ¼öÃà¿¡ °ü¿©Çϴ ±ÙÀ°¿¡ ÀÛ¿ëÀ» ÇÏ¿© ½ÉÀ嵿¸ÆÀ» À̿ϽÃÄѼ­ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù.
  
  ¨é º£Å¸Â÷´ÜÁ¦(beta-blocker): ½ÅüÀÇ ¿îµ¿·®À̳ª ±âŸÀÇ ¿ä±¸¿¡ ÀÇÇØ¼­ ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇϴ ½Å°æÀº ¹Ù·Î º£Å¸-±³°¨½Å°æÀÌ´Ù. ±³°¨½Å°æ°è¶õ »ç¶÷ÀÌ À§±ÞÇÑ »óȲ¿¡¼­ ÀÛ¿ëÇϴ ÀÚÀ²½Å°æ°èÀÌ´Ù. Áï »ç¶÷ÀÌ ±äÀåÇϰųª ½Î¿ï °æ¿ì¿¡ ÀüÇüÀûÀ¸·Î ±³°¨½Å°æ°è°¡ ÀÛ¿ëÇÑ´Ù. Áï ½ÉÀåÀÌ ¶Ù°Å³ª ¼ÒÈ­°¡ ¾ÊµÇ°Å³ª µ¿°øÀÌ Ä¿Áö´Â °Í µûÀ§°¡ ¹Ù·Î ±³°¨½Å°æ°èÀÇ ¿ªÇÒÀ̶ó°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ ±³°¨½Å°æ°è¿¡¼­ ¸»ÃÊÀå±â¿¡ º¸³»´Â ½Å°æÀÌ ±³°¨½Å°æÀÌ´Ù. ±×·¯¹Ç·Î ½ÉÀå¿¡¼­ ½ÉÀåÀ» ½Åü¿¡ Çʿ信 µû¶ó¼­ ¸¹Àº ÀÏÀ» ÇϰÔÇϴ ½Å°æÀ» Â÷´ÜÇÒ °æ¿ì¿¡´Â Çù½ÉÁõÀ» Ä¡·áÇÒ ¼ö ÀÖ°Ô µÈ´Ù(½ÉÀåÀÇ »ê¼Ò³ª ±âŸ ¿µ¾çºÐÀÇ ¼ö¿ä¸¦ ÁÙÀδÙ).
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antipruritic drug
    °¡·Á¿ò¾à
  • antipsychotic drug
    Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­Á¦
  • antiseborrheic drug
    Áö·ç¾à
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    1. ¹æºÎÁ¦ 2. »ì±ÕÁ¦
  • antithyroid drug
    °©»ó»ù¾à, Ç×°©»ó¼±Á¦
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adverse drug reaction
    ¾à¹°À¯ÇعÝÀÀ
  • crude drug
    »ý¾à
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • drug treatment
    ¾à¹°Ä¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸Á¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇÁ¦
  • antipruritic drug
    °¡·Á¿ò¾à
  • antipsychotic drug
    Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­Á¦
  • antiseborrheic drug
    Áö·ç¾à
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    Ç×±Õ¾à
  • antithyroid drug
    °©»ó»ù¾à, Ç×°©»ó»ù¾àÁ¦
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • arsenic drug
    ºñ¼Ò¾à
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiamebic drug
    Ç׾Ƹ޹پà.
  • antianxiety drug
    Ç׺ҾȾà(ù÷ÝÕäÌå·).
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´(Ä¡·á)¾à.
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î(¼º)¾à.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦, Ç×¹«½ºÄ«¸°(¼º)¾à
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸¾à (ù÷ÝþØ»å·).
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ¾à.
  • antipruritic drug
    Ç×¼Ò¾ç¾à£¬Áø¾ç¾à(òååÊå·), °¡·Á¿òÁ¦Áö¾à.
  • antipsychotic drug
    Ç×Á¤½Åº´¾à(ù÷ïñãêÜ»å·).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antiarrhythmic drug
    Ç׺ÎÁ¤¸ÆÁ¦.
  • anticancer drug
    Ç×¾ÏÁ¦.
  • anticoagulant drug
    Ç×ÀÀ°íÁ¦.
  • antidiabetic drug
    Ç×´ç´¢º´(Ä¡·á)¾à.
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î(¼º)¾à.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦, Ç×¹«½ºÄ«¸°(¼º)¾à
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸¾à (ù÷ÝþØ»å·).
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ¾à.
  • antipruritic drug
    Ç×¼Ò¾ç¾à£¬Áø¾ç¾à(òååÊå·), °¡·Á¿òÁ¦Áö¾à.
  • antipsychotic drug
    Ç×Á¤½Åº´¾à(ù÷ïñãêÜ»å·).
  • antipsychotic drug
    Ç×Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­¾à(ú°æðå·).
  • antiseborrheic drug
    Ç×Áö·ç¾à(¡­å·).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DUR drug use review; drug utilization review
IVDA/IVDU intravenous drug abuse/ abuser; intravenous drug use/user
Rx drug; medication; pharmacy; prescribe, prescription, prescription drug; take [Lat. recipe]; therapy;...
BOP buffalo orphan prototype [virus]
CELO chick embryonal lethal orphan [virus]
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AD Antidepressant drug
APD antipsychotic drug
CAD cationic amphiphilic drug
CDER Center for Drug Evaluation and Research
CIDR Controlled Internal Drug Release
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antiinflammatory drug
    ¼Ò¿°Á¦
  • antimalarial drug
    Ç׸»¶ó¸®¾ÆÁ¦
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ ¾à
  • antipsychotic drug
    Ç×Á¤½Åº´ ¾à, ÇâÁ¤½Åº´ ¾à¹°
  • antiseborrheic drug
    Ç×Áö·ç ¾à
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇìŸ ¾à
  • antithyroid drug
    Ç×°©»ó¼± ¾à
  • bioreductive drug
    »ýü ȯ¿ø¼º ¾àÁ¦
  • bullous drug-induced exanthema
    ¾à¹°¿¡ ÀÇÇÑ ¼öÆ÷¼º ¹ßÁø
  • calcium channel blocking drug
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°
  • cholinergic drug
    Äݸ° ÀÛ¿ë ¾à
  • common drug
    º¸Åë ¾à
  • depolarizing neuromuscular blocking drug
    Å»ºÐ±Ø¼º ½Å°æ±Ù ºÀ¼â ¾à¹°
  • designer drug
    º¯Á¶ ¾à¹°, ³²¿ë ¾à¹°
  • doping : the action of administering a drug to someone before a sports event
    originally to a horse before a race
    ; the substance thus administered.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
addictive drug Any drug that creates a certain degree of euphoria and has a strong potential for addiction.
(05 Mar 2000)
adverse drug reaction reporting systems Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
(12 Dec 1998)
akathisia, drug-induced Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation).
(12 Dec 1998)
antineoplastic drug A drug that stops or slows the maturation and spread of tumour cells (benign or malignant).
(09 Oct 1997)
maintenance drug therapy In chemotherapy, systematic dosage at a level that maintains protection against exacerbation.
(05 Mar 2000)
rational drug design <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it.
(17 Dec 1997)
receptors, drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behaviour of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified.
(12 Dec 1998)
recreational drug A controlled substance taken for non-medical purposes. Street drugs comprise various amphetamines, anaesthetics, barbiturates, opiates, and psychoactive drugs, and many are derived from natural sources (e.g., the plants Papaver somniferum, Cannibis sativa, Amanita pantherina, Lophophora williamsii). Slang names include acid (lysergic acid diethylamide), angel dust (phencyclidine), coke (cocaine), downers (barbiturates), grass (marijuana), hash (concentrated tetrahydrocannibinol), magic mushrooms (psilocybin), mescaline (peyote), speed (amphetamines). During the 1980s, a new class of "designer drugs" arose, mostly analogs of psychoactive substances intended to escape regulation under the Controlled Substances Act. Also, crack cocaine, a potent, smokable form of cocaine, emerged as a major public health problem. In the U.S. Illicit use of drugs such as cocaine, marijuana, and heroin historically has occurred in cycles.
Synonym: recreational drug.
(05 Mar 2000)
peak plasma drug concentration <pharmacology> The highest level of drug that can be obtained in the blood usually following multiple doses.
(09 Oct 1997)
chemotherapy drug sensitivity test <investigation> A test to assess a cancerous tissue's response and vulnerability to chemotherapy drugs. This test can help predict a patients response to treatment and suggest which drugs may be useful.
(16 Dec 1997)
metabolic detoxication, drug Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion.
(12 Dec 1998)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
crude drug Any raw or unrefined medicinal compound in its natural form, especiallyone taken from a plant.
(09 Oct 1997)
prescription drug A drug requiring a prescription, a physician's order. By comparison with an over-the-counter drug.
(12 Dec 1998)
prescriptions, drug Directions written for the preparation and adminstration of a drug.
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
orphan drug A designation of the FDA to indicate a therapy developed to treat a rare disease (one which afflicts a US population of less than 200,000 people). Because there are few financial incentives for drug companies to develop therapies for diseases that afflict so few people, the US government offers additional incentives to drug companies (ie tax advantages and extended marketing exclusivity) that develop these drugs.
Ãâó: www.wcctrials.com/glossary.HTM
orphan drug medicine used to treat diseases that occur rarely, generally not more than 5 in 10,000 persons; because there is little financial incentive for industry to develop them, the regulation of these products is different from normal medicines palindrome a segment of DNA or RNA that reads the same in both directions primer small nucleotide chain used as template by the DNA polymerase to synthesize a new DNA molecule sigma section of the colon with similar shape to the eighteenth letter of the ...
Ãâó: pages.britishlibrary.net/ana/Current%20medical%20w...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hard drug
    ½À°ü¼º ¸¶¾à
  • miracle drug
    Ưȿ¾à;¿µ¾à
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ÀǾàǰ
  • mood drug
    ±âºÐ ¾à(ÈïºÐÁ¦,ÁøÁ¤Á¦ µî)
  • prescription drug
    ÀÇ»çÀÇ Ã³¹æÀüÀÌ ÇÊ¿äÇÑ ¾à
  • soft drug
    ¾àÇÑ ¸¶¾à(¸¶¸®È­³ª µûÀ§)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á